{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:22:04Z","timestamp":1766269324234},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.sxmr.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T02:01:32Z","timestamp":1493172092000},"page":"143-156","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact"],"prefix":"10.1093","volume":"6","author":[{"given":"Andrew T.","family":"Gabrielson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan T.","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI102861","article-title":"Isolation and characterization of proteinase and collagenase from Cl. histolyticum","volume":"32","author":"Mandl","year":"1953","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.sxmr.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0363-5023(96)80368-6","article-title":"Collagenase in the treatment of Dupuytren's disease: an in\u00a0vitro study","volume":"21","author":"Starkweather","year":"1996","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.sxmr.2017.03.005_bib3","first-page":"48","article-title":"Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens","volume":"128","author":"Nyberg","year":"1982","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib4","first-page":"291","article-title":"The genetic and bacteriological aspects of Peyronie's disease","volume":"157","author":"Ralph","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie's disease experimental studies","volume":"10","author":"Gelbard","year":"1982","journal-title":"Urol Res"},{"key":"10.1016\/j.sxmr.2017.03.005_bib6","series-title":"Xiaflex \u00ae (collagenase Clostridium histolyticum)","year":"2016"},{"key":"10.1016\/j.sxmr.2017.03.005_bib7","first-page":"116","article-title":"Clostridium histolyticum collagenases: a new look at some old enzymes","volume":"1","author":"Mookhtiar","year":"1992","journal-title":"Matrix Suppl"},{"key":"10.1016\/j.sxmr.2017.03.005_bib8","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1021\/bi00344a032","article-title":"Complementary substrate specificities of class I and class II collagenases from Clostridium histolyticum","volume":"24","author":"Van Wart","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.sxmr.2017.03.005_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/bi00377a004","article-title":"Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns","volume":"10","author":"French","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.sxmr.2017.03.005_bib10","first-page":"280","article-title":"The use of collagenase in the treatment of Peyronie's disease","volume":"134","author":"Gelbard","year":"1985","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A\u00a0first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib12","series-title":"Collagenase Clostridium histolyticum degrades type I and III collagen while sparing type IV collagen in\u00a0vitro in Peyronie's plaque explants [abstract PD22-03]. Presented at: Annual Meeting of the American Urological Association Annual Meeting","author":"Levine","year":"2014"},{"key":"10.1016\/j.sxmr.2017.03.005_bib13","series-title":"Pharmacokinetics of a single treatment cycle of AA4500 0.58 mg in men with Peyronie's disease","year":"2011"},{"key":"10.1016\/j.sxmr.2017.03.005_bib14","first-page":"286","article-title":"Toxicity of collagenase: the relation to enzyme therapy of disk herniation","volume":"101","author":"Garvin","year":"1974","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.sxmr.2017.03.005_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib16","first-page":"2350","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib17","first-page":"1391","article-title":"Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression","volume":"158","author":"El-Sakka","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11934-005-0041-2","article-title":"Conservative management options for Peyronie's disease","volume":"6","author":"Jack","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.sxmr.2017.03.005_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0895-4356(98)00015-8","article-title":"A\u00a0case-control study on risk factors for Peyronie's disease","volume":"51","author":"Carrieri","year":"1998","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib20","first-page":"1529","article-title":"A\u00a0cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease","volume":"7","author":"Rhoden","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib21","series-title":"Campbell-Walsh urology","first-page":"792","article-title":"Peyronie's disease","author":"Jordan","year":"2007"},{"key":"10.1016\/j.sxmr.2017.03.005_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1464-410X.1982.tb13640.x","article-title":"Factors associated in the aetiology of peyronie's disease","volume":"54","author":"Chilton","year":"1982","journal-title":"Br J Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib23","first-page":"2115","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.12346","article-title":"Deformity stabilization and improvement in men with untreated Peyronie's disease","volume":"113","author":"Berookhim","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib25","first-page":"41","article-title":"Controlled clinical trial of vitamin E in Peyronie's disease","volume":"9","author":"Pryor","year":"1983","journal-title":"Prog Reprod Biol Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib26","first-page":"2003","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease","volume":"91","author":"Prieto Castro","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aja.2010.117","article-title":"Pentoxifylline treatment and penile calcifications in men with Peyronie's disease","volume":"13","author":"Smith","year":"2011","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2017.03.005_bib31","first-page":"905","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib32","first-page":"745","article-title":"American Urological Association Education and Research. Peyronie's disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib33","first-page":"1775","article-title":"Tunica albuginea tissue analysis after electromotive drug administration","volume":"169","author":"Levine","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib34","first-page":"477","article-title":"Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease\u2014a placebo-controlled pilot study","volume":"4","author":"Fitch","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib35","first-page":"972","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib36","first-page":"740","article-title":"Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials","volume":"171","author":"Hauck","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2007.06.032","article-title":"The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue","volume":"53","author":"M\u00fcller","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2006.10.042","article-title":"Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease","volume":"51","author":"Russell","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib39","first-page":"394","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib41","first-page":"117","article-title":"Intralesional verapamil injection versus placebo in Peyronie's disease","volume":"159","author":"Nicolai","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2015.03.010","article-title":"Intralesional injections for early Peyronie disease: standardized assessment and analysis of predictive factors for treatment response","volume":"86","author":"Wolff","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib45","first-page":"107","article-title":"Role of collagenase clostridium histolyticum in Peyronie's disease","volume":"9","author":"Peak","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.sxmr.2017.03.005_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042307-200411000-00008","article-title":"Peyronie's disease: advancements in recent surgical techniques","volume":"14","author":"Dean","year":"2004","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib47","first-page":"2149","article-title":"A\u00a0surgical algorithm for the treatment of Peyronie's disease","volume":"158","author":"Levine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib48","first-page":"280","article-title":"The use of collagenase in the treatment of Peyronie's disease","volume":"134","author":"Gelbard","year":"1985","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib49","first-page":"56","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib50","first-page":"180","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib51","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib52","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib53","first-page":"248","article-title":"Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib54","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib56","first-page":"125","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib57","first-page":"2492","article-title":"Comparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie's disease","volume":"12","author":"Yafi","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib58","first-page":"1704","article-title":"Intralesional injection of interferon-alpha2b improves penile curvature in men with Peyronie's disease independent of plaque location","volume":"194","author":"Stewart","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib59","unstructured":"Milam D. Positive results with collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie's disease [abstract 116]. Presented at: 21st Annual Fall Meeting of the Sexual Medicine Society of North America. 2015. Las Vegas, Nevada, November 19-22, 2015."},{"key":"10.1016\/j.sxmr.2017.03.005_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.sxmr.2016.07.004","article-title":"Review of management options for patients with atypical Peyronie's disease","volume":"5","author":"Yafi","year":"2017","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2017.03.005_bib61","first-page":"1667","article-title":"Male urethral stricture disease","volume":"177","author":"Santucci","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib62","first-page":"209","article-title":"Epidemiology of urethral strictures","volume":"3","author":"Alwaal","year":"2014","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2012.08.062","article-title":"Contemporary urethral stricture characteristics in the developed world","volume":"81","author":"Palminteri","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1464-410X.2007.06904.x","article-title":"A\u00a0morphometric analysis of bulbar urethral strictures","volume":"100","author":"Cavalcanti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib65","first-page":"805","article-title":"Extracellular matrix changes in urethral stricture disease","volume":"168","author":"Da-Silva","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib66","first-page":"548","article-title":"Clinical outcome and quality of life assessment in patients treated with perineal urethrostomy for anterior urethral stricture disease","volume":"182","author":"Barbagli","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOU.0b013e32835621a2","article-title":"Long-term effect of urethral dilatation and internal urethrotomy for urethral strictures","volume":"22","author":"Veeratterapillay","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib68","first-page":"1611","article-title":"Long-term results of internal urethrotomy","volume":"156","author":"Albers","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib69","first-page":"73","article-title":"Internal urethrotomy in the management of anterior urethral strictures: long-term follow-up","volume":"156","author":"Pansadoro","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib70","first-page":"1266","article-title":"Stricture recurrence after urethroplasty: a systematic review","volume":"182","author":"Meeks","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib71","first-page":"182","article-title":"Male urethral stricture: American Urological Association guideline","volume":"197","author":"Wessells","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib72","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ki.1995.407","article-title":"Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy","volume":"48","author":"Pimentel","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.sxmr.2017.03.005_bib73","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3181\/00379727-163-40750","article-title":"In\u00a0vitro inhibition of cell growth, collagen synthesis, and prolyl hydroxylase activity by triamcinolone acetonide","volume":"163","author":"McCoy","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.sxmr.2017.03.005_bib74","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1089\/end.2014.0090","article-title":"Efficacy and safety of local steroids for urethral strictures: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2014","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib75","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.eururo.2006.11.038","article-title":"Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy","volume":"51","author":"Mazdak","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib76","first-page":"629","article-title":"Isolation and characterization of collagen in Peyronie's disease","volume":"141","author":"Somers","year":"1989","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2017.03.005_bib77","doi-asserted-by":"crossref","first-page":"647.e1","DOI":"10.1016\/j.urology.2015.06.013","article-title":"Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis","volume":"86","author":"Sangkum","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2017.03.005_bib78","author":"Wiegand"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052117300355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052117300355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:36:51Z","timestamp":1672774611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052117300355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2050052117300355"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2017.03.005","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}